DeepCure, developer of small molecule therapeutics using an AI-enabled drug discovery platform, raised $40 million in Series A funding.
The round was led by Morningside Ventures with participation from existing investors TLV Partners, Sapir Venture Partners and Benon Group Ltd.
DeepCure said the Series A brings its total raise to $47 million.
WHAT IT DOES
The company uses its AI engine to develop...
Tech-enabled drug discovery company Valo Health announced today plans to go public through a $2.8 billion SPAC deal with Khosla Ventures Acquisition Co., a special purpose acquisition company from Khosla Ventures.
The deal, which is expected to close in the third quarter of this year, will deliver approximately $168.5 million in proceeds in private investment in public equity (PIPE) funding from...
French artificial intelligence (AI) startup Iktos and drug discovery firm Facio Therapies have announced they are collaborating to design treatment for the skeletal muscle wasting condition facioscapulohumeral dystrophy (FSHD).
Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling AI technologies in one of Facio’s drug discovery programmes.
The...
insitro, an artificial intelligence drug discovery startup, has added a $400 million Series C round to its already impressive fundraising haul. The financing is set to close during the first full week of April, according to the company.
Canadian Pension Plan Investment Board led the raise, which also included a laundry list of participants. These names include: Andreessen Horowitz, funds and...
This morning Israeli "Digital X-ray" company Nanox announced a new deal with medical data and image management firm Ambra Health. The agreement will see Ambra's cloud software integrated with the digital component of Nanox's in-development imaging systems, and according to the companies will streamline image management while making it easier to access for providers and patients.
"It is our intent...
insitro and Exscientia, two platforms using artificial intelligence to drive the discovery of new drugs, announced this morning the raise of $143 million and $60 million, respectively, from investors.
insitro's oversubscribed Series B round was headed by Andreessen Horowitz, and joined by new backers Canada Pension Plan Investment Board, T. Rowe Price Associates, BlackRock, Casdin Capital, HOF...
German pharma giant Bayer and British biotech firm Exscientia have announced a three-year partnership focused on the use of Artificial Intelligence in cardiovascular and oncology drug discovery.
The collaboration will initially see the companies work on three early-stage research projects, combining Bayer’s data and drug discovery capabilities and Exscientia’s Centaur Chemist platform.
According...
Novartis is teaming up with Microsoft on a new artificial intelligence initiative focused on drug discovery and development. The new efforts will primarily be focused in Novartis’ newly announced AI innovation lab.
As part of the deal Novartis will be employing Microsoft’s AI tools to help its scientist with computational hurdles in life sciences including generative chemistry, image...
In a recent medium.com blog post, Daphne Koller — an artificial intelligence researcher at the Department of Computer Science at Stanford University and, until just a few months ago, chief computing officer at Alphabet’s Calico Labs — announced her up-and-coming foray into machine learning-powered drug discovery.
Called insitro (a portmanteau of “in silico” and “in vitro”), the new endeavor looks...
BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States. Existing backer Woodford Investment Management also participated in the round, which brings the company’s total funds raised to over $200 million.
“We are very pleased with the response to the fundraising," Ken Mulvany,...
.jpg?itok=9G0Ofi7Z)
.jpeg?itok=4rSQL_F6 "The partnership will work on a drug discovery programme for the genetic muscle wasting disorder.")
